PureTech Health PLC (LON:PRTC) said its affiliate company has inked a major deal with a Japanese pharma worth US$20mln upfront and up to US$105mln in potential milestone payments.
The firm, Akili, is developing digital medicines AKL-T01 and AKL-T02.
The former is currently under review with the US Food and Drug Administration as a potential digital treatment for children with attention-deficit hyperactivity disorder, while the latter is in late-stage trials in children with an autism spectrum disorder.
The partnership with Shionogi & Co covers the markets of Japan and Korea.